Every publicly traded biotechnology company lives through a series of binary events and inflection points. It’s simply the nature of the fickle investor beast. Sometimes, a series of these milestone events meet in a perfect storm of possibility. That’s what 2019 is shaping up to be for Q BioMed (OTCQB: QBIO), a company that just may have a better mousetrap to accelerate the monetization of biomedical technologies. Q BioMed has a depth and breadth of platform that is rarely found among such young biotechnology companies. Founded less than six years ago, the company is focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed’s strategy has been to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. The company aims to develop these assets to provide shareholder returns via organic growth, revenue production, out-licensing, sale or spinoff of new public companies. The company has four distinct programs across the spectrum of development stages. Q BioMed anticipates making tangible progress in all programs this year, with demonstrable milestones expected to be achieved in each program. Metastron™ (Strontium Chloride 89) -FDA-approved Metastron is the company’s non-opioid pain reliever for palliative treatment of bone pain from cancer metastases. · The drug is already FDA-approved, and the company is awaiting FDA review of a new cGMP manufacturing facility. · Q BioMed expects to generate revenue from Metastron in the first half of 2019 · A Phase 4 post-marketing study for an expanded therapeutic label is expected to begin in the fourth quarter of 2019 QBM-001 for Rare Pediatric Non-Verbal Disorder—an Autism Spectrum Disorder QBM-001 acts as a regulator of faulty membrane channels in the brain that are known to cause migraines and/or seizures. Regulation of these channels would allow QBM-001 to potentially alleviate non-verbal disorder and allow toddlers to actively develop language and avoid life-long speech and intellectual impairment. · The program was featured in the February issue of DDNews, a monthly newspaper dedicated to the news of technology and business in the pharmaceutical and biotechnology industries, whose web usage generates over 4.6 million downloaded pages a year. · Pre-IND Filing and0 Orphan Drug Filing are expected with the FDA in the first half of 2019 · A 5-year pivotal clinical trial is expected to begin in the second half of 2019 Uttroside-B Chemotherapy for Liver Cancer Uttroside-B appears to affect pro survival signaling and cell death in a variety of liver cancer cell types. · Provisional patent has been filed, and molecule synthesis was completed in December 2018 · Completing pre-clinical work now. Proof of concept studies will be done in the first half of 2019 · We expect to file an IND in the third quarter of 2019 MAN-01 for Primary Open-Angle Glaucoma MAN-01 is a topical eye drop for glaucoma, whose novel mechanism of action targets Schlemm’s Canal which is responsible for 70%-90% of fluid drainage in the eye. · Completing molecule optimization for eye drop formulation · Initiating pre-IND studies in the first half of 2019 · We expect to file an IND in 2019 · We have formalized additional indications including acute kidney injury, cardiovascular disease and infectious disease. Q BioMed stock has rebounded well from its $0.90 lows at Christmastime and is currently at $1.66 as of afternoon trading on March 7th. The current market cap of $24 million seems very light for a company that’s anticipated to hit milestones across its portfolio in 2019.
For consideration of being featured on WallstreetPR, contact editor@Wallstreetpr.com